Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 2
Submit an article Journal homepage
167
Views
6
CrossRef citations to date
0
Altmetric
Special Report

The challenges of translating stem cells for spinal cord injury and related disorders: what are the barriers and opportunities?

Stephanie M Hewson Division of Neurosurgery, University of Toronto, ON, Canada; Division of Neurosurgery, University of Toronto, ON, Canada
,
Lauren N Fehlings Division of Neurosurgery, University of Toronto, ON, Canada; Division of Neurosurgery, University of Toronto, ON, Canada
,
Mark Messih Division of Neurosurgery, University of Toronto, ON, Canada; Division of Neurosurgery, University of Toronto, ON, Canada
&
Michael G Fehlings Division of Neurosurgery, University of Toronto, ON, Canada; Krembil Neuroscience Center, Toronto Western Hospital, ON, Canada. [email protected]; Krembil Chair, Neural Repair and Regeneration, Head, Spinal Program, University Health Network, Toronto, ON, Canada; Krembil Neuroscience Program, The Toronto Western Hospital, University Health Network, Room 4W–449, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada; Krembil Neuroscience Center, Toronto Western Hospital, ON, Canada. [email protected]
Pages 143-150 | Published online: 09 Jan 2014

References

  • Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 26(Suppl. 24), S2–S12 (2001).
  • Anonymous. Spinal cord injury facts and figures at a glance. J. Spinal Cord Med. 35(1) 68–69 (2012).
  • Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J. Neurosurg. 75(1), 15–26 (1991).
  • Hyun JK, Kim HW. Clinical and experimental advances in regeneration of spinal cord injury. J. Tissue Eng. 2010, 650857 (2010).
  • Fehlings MG, Vawda R. Cellular treatments for spinal cord injury: the time is right for clinical trials. Neurotherapeutics 8(4), 704–720 (2011).
  • Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders – time for clinical translation? J. Clin. Invest 120(1), 29–40 (2010).
  • Coutts M, Keirstead HS. Stem cells for the treatment of spinal cord injury. Exp. Neurol. 209(2), 368–377 (2010).
  • Crozier GKD, Thomson K. Stem cell tourism and the role of health professional organizations. Am. J. Bioeth. 10(5), 36–38 (2010).
  • Illes J, Reimer JC, Kwon BK. Stem cell clinical trials for spinal cord injury: readiness, reluctance, redefinition. Stem Cell Rev. 7(4), 997–1005 (2011).
  • Kimmelman J, London AJ. Predicting harms and benefits in translation trials: ethics, evidence and uncertainty. PLoS Med 8(1), 1–5 (2010).
  • Kwon BK, Hillyer J, Tetzlaff W. Translational research in spinal cord injury: a survey of opinion from the SCI community. J. Neurotrauma 27(1), 21–33 (2010).
  • Yim R. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient’s bedside. Transfusion 45(Suppl. 4), 144S–158S (2005).
  • Miller RH, Bai L. Translating stem cell therapies to the clinic. Neurosci. Lett. 519(2), 87–92 (2012).
  • Trounson A. Integration and translation: driving stem cell therapies toward the clinic. Regen. Med. 3(3), 269–273 (2008).
  • Watson RA, Yeung TM. What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury? BMC Neurol. 11, 113 (2011).
  • Amador MJ, Guest JD. An appraisal of ongoing experimental procedures in human spinal cord injury. J. Neurol. Phys. Ther. 29(2), 70–86 (2005).
  • Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg. Focus 25(5), E2 (2008).
  • Rosenfeld JV, Bandopadhayay P, Goldschlager T, Brown DJ. The ethics of the treatment of spinal cord injury: stem cell transplants, motor neuroprosthetics and social equity. Spinal Cord Inj. Rehabil. 14(1), 76–88 (2010).
  • Hyun I, Lindvall O, Ahrlund-Richter L et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 3(6), 607–609 (2008).
  • Chien KR. Stem cells: lost in translation. Nature 428(6983), 607–608 (2004).
  • Kwon BK, Hillyer J, Tetzlaff W. Translational research in spinal cord injury: a survey of opinion from the SCI community. J. Neurotrauma 27(1), 21–33 (2010).
  • Mathews DJ, Sugarman J, Bok H et al. Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology 71(4), 288–293 (2008).
  • Lo B, Kriegstein A, Grady D. Clinical trials in stem cell transplantation: guidelines for scientific and ethical review. Clin. Trials 5(5), 517–522 (2008).
  • Cohen CB, Cohen PJ. International stem cell tourism and the need for effective regulation: Part I: Stem cell tourism in Russia and India: clinical research, innovative treatment, or unproven hype? Kennedy Inst. Ethics J. 20(1), 27–49 (2010).
  • Magnus D. Translating stem cell research: challenges at the research frontier. J. Law. Med. Ethics 38(2), 267–276 (2010).
  • Vogel G. Cell biology. Ready or not? Human ES cells head toward the clinic. Science 308(5728), 1534–1538 (2005).
  • Rosenfeld JV, Gillett GR. Ethics, stem cells and spinal cord repair. Med. J. Aust. 180(12), 637–639 (2004).
  • Cohen CB, Cohen PJ. International stem cell tourism and the need for effective regulation. Part II: Developing sound oversight measures and effective patient support. Kennedy Inst. Ethics J. 20(3), 207–230 (2010).
  • Pandya SK. Stem cell transplantation in India: tall claims, questionable ethics. Indian J. Med. Ethics 5(1), 15–17 (2008).
  • Dobkin BH, Curt A, Guest J. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil. Neural Repair 20(1), 5–13 (2006).
  • Blight A, Curt A, Ditunno JF et al. Position statement on the sale of unproven cellular therapies for spinal cord injury: the international campaign for cures of spinal cord injury paralysis. Spinal Cord 47(9), 713–714 (2009).
  • Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3(6), 591–594 (2008).
  • Jayaraman KS. India makes waves over tsunami warning system. Nature 438(7071), 1060–1061 (2005).
  • Anonymous. The darker side of stem cells. Nature 483(7387), 5 (2012).
  • McLaren A. Ethical and social considerations of stem cell research. Nature 414(6859), 129–131 (2001).
  • Lo B, Parham L. Resolving ethical issues in stem cell clinical trials: the example of Parkinson disease. J. Law. Med. Ethics 38(2), 257–266 (2010).
  • Bretzner F, Gilbert F, Baylis F, Brownstone RM. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8(5), 468–475 (2011).
  • Wirth E 3rd, Lebkowski JS, Lebacqz K. Response to Frederic Bretzner et al. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8(5), 476–478 (2011).
  • Solbakk JH, Zoloth L. The tragedy of translation: the case of ‘first use’ in human embryonic stem cell research. Cell Stem Cell 8(5), 479–481 (2011).
  • Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising basic science research into clinical applications. Am. J. Med. 114(6), 477–484 (2003).
  • Lebkowski J. GRNOPC1: the world’s first embryonic stem cell-derived therapy. Interview with Jane Lebkowski. Regen. Med. 6(Suppl. 6), 11–13 (2011).
  • Levine AD. Insights from patients’ blogs and the need for systematic data on stem cell tourism. Am. J. Bioeth. 10(5), 28–29 (2010).
  • Ilic D. Industry highlights: Stem cell and regenerative medicine. Regen. Med. 6(Suppl. 6), 55–60 (2011).
  • Zarzeczny A, Caulfield T. Emerging ethical, legal and social issues associated with stem cell research & and the current role of the moral status of the embryo. Stem Cell Rev. 5(2), 96–101 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.